103261-68-3

Basic information

• Product Name: 5-Cyano-2-methyl-benzoic acid methyl ester
• Synonyms: 5-Cyano-2-methyl-benzoic acid methyl ester;methyl 5-cyano-2-methylbenzoate;Benzoic acid, 5-cyano-2-methyl-, methyl ester
• CAS NO: 103261-68-3
• Molecular Formula: C₁₀H₉NO₂
• Molecular Weight: 175.18396
• Mol File: 103261-68-3.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 288.4±28.0 °C(Predicted)
• Appearance: /
• Density: 1.15±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-Cyano-2-methyl-benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Cyano-2-methyl-benzoic acid methyl ester(103261-68-3)
• EPA Substance Registry System: 5-Cyano-2-methyl-benzoic acid methyl ester(103261-68-3)

Safety Data

• Hazardous Substances Data: 103261-68-3(Hazardous Substances Data)

Usage

General Description

5-Cyano-2-methyl-benzoic acid methyl ester is a chemical compound with the molecular formula C10H9NO2. It is a methyl ester derivative of 5-Cyano-2-methylbenzoic acid and is commonly used in organic synthesis and as an intermediate in the production of pharmaceuticals and agrochemicals. It is a white crystalline solid with a melting point of 147-149°C and is soluble in organic solvents such as acetone, ether, and chloroform. 5-Cyano-2-methyl-benzoic acid methyl ester is often utilized as a building block in the synthesis of various pharmaceutical and agrochemical compounds due to its functional groups and thermal stability. It is important for researchers and chemists working in drug discovery and development.

Upstream product

• 186581-53-3 diazomethane 
• 1943-88-0 2,4-dicyanotoluene 
• 21423-81-4 3-chloro-4-methylbenzonitrile 
• 18595-12-5 methyl 5-amino-2-methylbenzoate 
• 544-92-3 copper(I) cyanide 
• 151-50-8 potassium cyanide 
• 67-56-1 methanol 
• 773837-37-9 sodium cyanide 
• 79669-50-4 methyl 2-methyl-5-bromobenzoate 
• 60710-80-7 5-cyano-2-methylaniline 
• 39478-78-9 5-bromo-2-methylaniline 
• 1975-54-8 3-cyano-6-methylbenzoic acid 
• 201230-82-2 carbon monoxide 
• 42872-79-7 3-iodo-4-methylbenzonitrile 

Downstream Products

• 421551-82-8 methyl 2-(bromomethyl)-5-cyanobenzoate 
• 668262-61-1 methyl 5-cyano-2-(2-{3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]phenyl}ethenyl)benzoate 
• 668262-50-8 methyl 2-{[bromo(triphenyl)phosphoranyl]methyl}-5-cyanobenzoate 
• 1184301-84-5 methyl 5-(((tert-butoxycarbonyl)amino)methyl)-2-methylbenzoate 
• 1184301-85-6 5-(N-tert-butoxycarbonylmethyl)methylamino-2-methylbenzoic acid methyl ester 

Relevant articles and documents

HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME

A heterocyclic compound represented by formula XI, a pharmaceutically acceptable salt, a solvate, or a solvate of a pharmaceutically acceptable salt thereof, use thereof, and a composition containing the same. The compound is novel in structure and has good STAT5 inhibitory activity.

Compound and use in preparation of medicaments for treatment of malaria

The invention provides a compound which is a compound shown as a formula (I) or a stereoisomer, a tautomer, nitric oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compound shown as the formula (I). The compound can act on a plurality of targets, such as PfNDH2 enzyme and Pfbc1 enzyme so that growth and metabolism of plasmodium are effectively inhibited. Moreover, the compound has good absorbability, relatively high biological activity and availability and low toxicity and particularly has relatively strong stability in vivo and is not easy to decompose and long in drug effect time so that an effect of treating malaria is achieved and the compound has a good application prospect.

HETEROCYCLIC COMPOUND

The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.